[Anesthesia and implantable automatic defibrillator].
Since the introduction of first generation automatic implantable cardioverter defibrillators (AICD) in 1980, an increasing number of such devices have been inserted in patients at high risk for sudden death by ventricular tachycardia or fibrillation (VT/VF). With the improvement of technology and implanting techniques, devices may be inserted at present subcutaneously into the abdominal or the thoracic wall, rather than by thoracotomy. The anaesthesist is involved in the primary implantation of the AICD and the secondary testing of efficiency. Implantation generally requires general anaesthesia and the extension of monitoring is guided by the patient's underlying disease(s). The efficiency of the implanted system is tested one to two months later in inducing VT/VF under general anaesthesia and in determining the defibrillation threshold. The anaesthetist may also have to take care of patients with a AICD. For such cases the following recommendations can be made: a) gloves should be worn by doctors and nurses coming into contact with these patients, in order to limit the risk of electrification; b) a ring magnet must be available to inactivate the unit; c) in case of external defibrillation, the external paddles should be oriented perpendicularly to the line joining the two implanted electrodes; d) AICD should be disabled during electrocautery and prior to electroconvulsive therapy; e) the assistance of a electrophysiologist may be helpful for the management of these patients.
Stojeba
N
N
Service d'anesthésie-réanimation chirurgicale, hôpital de Hautepierre, Strasbourg, France.
Steib
A
A
Fournier
S
S
Loewenthal
A
A
Chauvin
M
M
D000758:Anesthesia / Q000379:methods*; D017147:Defibrillators, Implantable; D004564:Electrocoagulation / Q000009:adverse effects; D004868:Equipment Failure; D004869:Equipment Safety; D006801:Humans; D007431:Intraoperative Complications
Anesthésie et défibrillateur automatique implantable.